Sustained release of an Anti-Glaucoma drug: Demonstration of efficacy of a liposomal formulation in the rabbit eye

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Natarajan, Jayaganesh V ^a   Chattopadhyay, Sujay ^a,b   Ang, Marcus ^c   Darwitan, Anastasia ^a   Foo, Selin ^c   Zhen, Ma ^a   Koo, Magdalene ^c   Wong, Tina T ^a,c,d   Venkatraman, Subbu S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b DR BABASAHEB AMBEDKAR TECHNOLOGICAL UNIVERSITY   (India)

^c Singapore National Eye Centre   (Switzerland)

^d Singapore Eye Research Institute   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; LATANOPROST; LIPOSOME; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG STORAGE; FEMALE; IN VITRO STUDY; LIPID BILAYER; MOLECULAR STABILITY; NONHUMAN; RABBIT; SUSTAINED RELEASE FORMULATION; ANIMAL; CHEMISTRY; CONJUNCTIVA; DELAYED RELEASE FORMULATION; DRUG EFFECT; GLAUCOMA; METHODOLOGY; TOPICAL DRUG ADMINISTRATION;

ORYCTOLAGUS CUNICULUS;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CONJUNCTIVA; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GLAUCOMA; LIPID BILAYERS; LIPOSOMES; PROSTAGLANDINS F, SYNTHETIC; RABBITS;

EID: 80052601843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024513     Document Type: Article

References (48)

1. Quigley HA, (1996) Number of people with glaucoma worldwide. Br J Opthalmol 80: 389-393.
2. Radhakrishnan S, Iwach A, (2008) Glaucoma medication and its side effects. Glaucoma Research Foundation website: Gleams. Available: http://www.glaucoma.org/treatment/glaucoma-medications-and-their-side-effects.php. Accessed 2011 Aug 16.
3. Nordmann JP, Auzanneau N, Ricard S, Berdeaux G, (2003) Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. Available: http://www.hqlo.com/content/1/1/75. Accessed 2011 Aug 16.
4. Lewis TL, Barnedy HS, Barlett JD, Blume AJ, Fingeret M, et al. (2002) Optometric clinical practice guidelines care of the patient with open angle glaucoma. Reference guide for clinicians. American Optometric Association, 2nd edition.
5. Jonescu-Cuypers C, Jacobi P, Konene W, Krieglstein G, (2001) Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma. A randomized clinical trial. Ophthalmology 108: 254-258.
6. Quigley HA, Tielsch JM, Katz J, Sommer A, (1996) Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual filed damage. Am J Ophthalmol 122: 355-363.
7. Ritch R, Liebmann JM, (2001) Exfoliation syndrome and exfoliation glaucoma. In: Fingeret M, Lewis TL, editors. Primary care of the glaucomas, 2nd edition New York pp. 443-459.
8. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, et al. (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132: 472-484.
9. Lee VHL, (1990) Mechanisms and facilitation of corneal drug penetration. J Control Release 11: 79-90.
10. Rojanasakul Y, Robinson JR, (1989) Transport mechanisms of the cornea: characterization of barrier permselectivity. Int J Pharm 55: 237-246.
11. Yusuke S, Shin-Ichi Y, Akira O, (2005) Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol. Int J Pharm 305: 176-179.
12. Linden C, Nuija E, Alm A, (1997) Effect of IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and hypertension. Br J Ophtalmol 81: 370-372.
13. Lang JC, (1995) Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 16: 39-43.
14. Kaur IP, Kanwar M, (2002) Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28: 473-493.
15. Lee VHL, Urrea PT, Smith RE, Schanzlin DJ, (1985) Ocular drug bioavailability from topically applied liposomes. Surv Opthalmol 2: 335-348.
16. Niesmann MR, (1992) The use of liposomes as drug carriers in ophthalmology. Crit Rev Ther Drug Carrier Syst 9: 1-38.
17. Ebrahim S, Peyman GA, Lee PJ, (2005) Applications of liposomes in ophthalmology. Surv Ophthalmol 50: 167-182.
18. Rojanasakul Y, Robinson JR, (1991) The cytoskeleton of the cornea and its role in tight junction permeability. Int J Pharm 68: 135-149.
19. Meisner D, Mezei M, (1981) Liposome ocular delivery systems. Adv Drug Del Rev 16: 75-93.
20. Smolin G, Okumoto M, Feiler S, Condon D, (1981) Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 91: 220-225.
21. Schaeffer HE, Krohn DK, (1982) Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 22: 220-227.
22. Lin HH, Ko SM, Hsu LR, Tsai YH, (1996) The preparation of norfloxacin-loaded liposomes and their in-vitro evaluation in pig's eye. J Pharm Pharmacol 48: 801-805.
23. Lee VHL, Takemoto KA, Iimoto DS, (1984) Precorneal factors influencing the ocular distribution of topically applied liposomal inulin. Curr Eye Res 3: 585-591.
24. Stratford RE Jr, Yang DC, Redell MA, Lee VHL, (1983) Ocular distribution of liposome encapsulated epinephrine and inulin in the albino rabbit. Curr Eye Res 2: 377-386.
25. Hathout RM, Mansour S, Mortada ND, Guinedi AS, (2007) Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm Sci Tech 8: 1-12.
26. Hirnle E, Hirnle P, Wright JK, (1991) Distribution of liposome incorporated carboxyfluorescein in rabbit eyes. J Microencapsul 8: 391-399.
27. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, et al. (2009) Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release 136: 247-253.
28. Almog R, Forward R, Samsonoff C, (1991) Stability of sonicated aqueous suspensions of phospholipids under air. Chem Phys Lipids 60: 93-99.
29. Wells AP, Crowston JG, Marks J, Kirwan JF, Simth G, et al. (2004) A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma 13: 454-460.
30. Shah M, Foreman DM, Ferguson MW, (1994) Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107: 1137-1157.
31. Bartlett GR, (1959) Phosphorus assay in column chromatography. J Biol Chem 234: 466-468.
32. Costas D, (2008) Differential Scanning Calorimetry (DSC): A tool to study the thermal behavior of lipid bilayers and liposomal stability. J Liposome Res 18: 159-173.
33. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, et al. (2004) Drug delivery systems for vitreoretinal disease. Prog Retin Eye Res 23: 253-281.
34. Amano S, Nakai Y, Ko A, Inoue K, Wakakura M, (2008) A case of keratoconus progression associated with the use of topical latanoprost. Jpn J Ophthalmol 52: 334-336.
35. Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y, (2004) Liposome formulation of poorly water soluble drugs: optimization of drug loading and ESEM analysis of stability. Int J Pharm 285: 23-34.
36. Perez-Soler R, Khokhar AR, (1992) Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res 52: 6341-6347.
37. Mehnert W, Mäder K, (2001) Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
38. Mannock DA, Lewis RN, McElhaney RN, (2010) A calorimetric and spectroscopic comparison of the effects of ergosterol and cholesterol on the thermotropic phase behavior and organization of dipalmitoylphosphatidylcholine bilayer membranes. Biochim Biophys Acta 1798: 376-388.
39. Bito LZ, (1986) Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma. US Patent No. 4,599, 353.
40. Liu J, Lee H, Huesca M, Young A, Christine A, (2006) Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy. Cancer Chemother Pharmacol 58: 306-318.
41. Detoni CB, Cabral-Albuquerque ECM, Hohlemweger SVA, Sampaio C, Barros TF, et al. (2009) Essential oil from Zanthoxylum tingoassuiba loaded into multilamellar liposomes useful as antimicrobial agents. J Microencapsul 26: 684-691.
42. Baker R, (1987) Controlled release of biologically active agents New York John Wiley and Sons.
43. Bolean M, Simão AM, Favarin BZ, Millán JL, Ciancaglini P, (2010) The effect of cholesterol on the reconstitution of alkaline phosphatase into liposomes. Biophys Chem 152: 74-79.
44. Halling KK, Slotte JP, (2004) Membrane properties of plant sterols in phospholipid bilayers as determined by differential scanning calorimetry, resonance energy transfer and detergent-induced solubilization. Biochim Biophys Acta 1664: 161-171.
45. Nagle JF, Nagle ST, (2000) Structure of lipid bilayers. Biochim Biophys Acta 1469: 159-195.
46. Huq F, (2007) Molecular modeling analysis of the metabolism of latanoprost. J Pharmacology and Toxicology 2: 359-365.
47. Sila-on W, Vardhanabhuti N, Ongpipattanakul B, Kulvanich P, (2008) Influence of incorporation methods on partitioning behavior of lipophilic drugs into various phases of a parenteral lipid emulsion. AAPS Pharma Sci Tech 9: 684-692.
48. Russo A, Riva I, Pizzolante T, Noto F, Quaranta L, (2008) Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol 2: 897-905.